Progress on funding mix in FY21 a positive; FY22e EPS down 26% to factor in potential provisioning; TP cut to…

While the potential capital raise will be a near-term overhang on the stock, with market share shifts set to accelerate,…

Tata is regaining share in PVs, will launch a new SUV in 2HCY21 and is leading in EVs. We retain…

Continuance of curbs on digital platforms to delay launches; valuation is attractive; ‘Buy’ retained with target price of Rs 1,900

This segment is presently < 5% of sales. In Q1, it posted healthy revenue growth of +68%, though EBIT margin…

Staff cost is a headwind; jump in capex is dragging cash flows; outlook for firm is lacklustre; estimates fine-tuned; ‘Hold’…

Following a strong 1Q, we raise FY22-24 revenue estimates by around 10-20%, primarily based on higher GOV (which in turn…

Gross margin pressure accentuated but Ebitda margins marginally expanded, led by operating leverage, lower A&P – international fared much better.

Bank’s priority is likely to continue affecting growth; FY22-23 EPS down 4%; TP up to `550; stock among key picks;…

Spike in Covid claims and provision; VNB CAGR of 21% estimated over FY21-24; Buy retained with TP of Rs 750

Its discount to HDFCB’s vals has narrowed to 35-40%, but val at 2.1x is attractive & disc. could narrow to…

VNB CAGR of 19% estimated over FY21-24; ‘Buy’ retained with TP lowered to Rs 800

CROMPTON further streamlined its Go-To-Market, and doubled retailers reach. 80% of its secondary sales can now be tracked, New launches…

Slippages likely to fall from Q2; biz trends from July close to normal/pre-Covid levels; ‘Buy’ retained with a target price…

ZyCoV-D filed in India for EUA: CDH has filed for emergency use authorisation (EUA) for ZyCoV-D, its plasmid DNA vaccine…